New trends in chemotherapy of the brain tumors - Treatment according to tumor types;Nove trendy v chemoterapii nadoru mozku - Lecba dle histologickych diagnoz

Klinicka Onkologie

Volumn 13, Issue 4, 2000, Pages 107-111

  Kala, M ^a   Cwiertka, K ^a   Hajdujch, M ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Astrocytoma; Chemotherapy; Glioblastoma; Malignant brain tumours; Oligodendroglioma; Primary nervous system lymphoma

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; IDARUBICIN; LOMUSTINE; METHOTREXATE; ONDANSETRON; PREDNISOLONE; PROCARBAZINE; TAXOL; TROPISETRON; VINCRISTINE;

ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; DRUG INDUCED DISEASE; GLIOBLASTOMA; HUMAN; OLIGODENDROGLIOMA; OTOTOXICITY; REVIEW; VOMITING;

EID: 0033805590     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Differential response by human melanoma cells to 1,3-bis- (2-chloroethyl) -1- nitrosourea and bleomycin
2. Rationale for preirradiation chemotherapy in treatment of malignant gliomas
3. Intracranial tumors: Response an resistance to therapeutic endeavours, 1970-1980
4. Medical research council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BRO5
5. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
6. Growth and chemotherapeutic response in athymic mice of tumours arising from human glioma-derived cell lines
7. Idarubicin for treatment of recurrent malignant glial tumors: A Buffalo-Rochester-Syracuse neuro-oncology study group trial
8. Chemotherapy for anaplastic oligodendroglioma
9. A multi-center, open label, single arm phase II study of RMP-7 and carboplatin, administered intra-arterially for the treatment of malignant glioma
10. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?
11. Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults. A phase II study
12. Non-AIDS primary CNS lymphoma: The first example of durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy
13. Combined modality therapy for primary CNS lymphoma
14. Screening of 12 gliomata against chemotherapeutic agents in vitro
15. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma
16. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
17. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
18. Primary central nervous system lymphoma
19. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain
20. High-dose methotrexate for non-AIDS primary central nervous system lymphoma
21. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results
22. Study on the effect of actinomycins in tissue cultures from human brain tumours
23. The treatment of oligodendrogliomas and mixed oligodendroglioma - Astrocytomas with PCV chemotherapy
24. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors
25. Decrease in vitro chemosensitivity of tumour cells in patients suffering from malignant diseases with a poor prognosis
26. Evaluation of lipid-coated microbubbles as a delivery vehicle for taxol in brain tumor therapy
27. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors
28. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
29. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors
30. Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors
31. Treatment of malignant brain tumor by local injection of Adriamycin
32. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
33. In vitro drug sensitivity testing in human gliomas
34. Protinadorova chemoterapie
35. Variations in response of human brain tumors to BCNU in vitro
36. Response of cultured human brain tumors to nitrosoureas: Correlation with clinical data
37. The role of cytotoxic chemotherapy in the treatment of malignant brain tumors
38. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means
39. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers
40. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
41. Modified procarbazine, CCNU and vincistine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors
42. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine
43. Intracarotid cisplatin chemotherapy for recurrent gliomas
44. Low grade oligodendroglioma responds to chemotherapy
45. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7
46. Medical research council (MRC) randomised trial of adjuvant chemotherapy in primary CNS lymphoma (PCL) -BRO6
47. Response of cultured glioblastomas to radiation and BCNU chemotherapy
48. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres
49. Rezistence nadorovych bunek na cytostatika a jeji vyznam v lecbe detske akutni leukemie
50. Nase prvni zkusenosti s testovanim rezistence nadorovych bunek na cytostatika
51. Muze citlivost nadorovych bunek na cytostatika ovlivnit klinickou odpoved deti s akutni lymfoblastickou leukemii?
52. Differential chemosensitivity of leukaemic cells in myeloid and lymphoid phase of stem cell leukaemia
53. What is the prognostic value of in vitro drag resistance assay in childhood ALL in short-term clinical outcome?
54. Analysis of correlation between drug resistance and clinical/laboratory measures found in a group of children with ALL treated by ALL BFM 90 protocol
55. Bleomycin and brain tumors.: A review
56. Intracavitary chemotherapy with 5-fluoro-2-deoxyuridine (FDURD) in the malignant brain tumors
57. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function
58. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity
59. Phase I trial of temozolomide (CCRG 81045: M and B39831: NSC 362856)
60. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: A pilot study
61. The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I - Evaluation of test - Specific variables
62. The MTT assay for chemosensitivity testing of human tumors of the central nervous system: Part II-evaluation of patient and drug - Specific variables
63. Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML
64. Clinical application of a sustained release anticancer pellet
65. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
66. Direct delivery of platinum-based antineoplastics to the central nervous system: A toxicity and ultrastructural study
67. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat
68. Phase I study of escalating doses of interstitial BCNU administered via wafer in patients with recurrent malignant glioma
69. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma
70. Intralesional chemotherapy with doxorubicin of brain gliomas
71. Primarni lymfom centralni nervove soustavy
72. Salvage chemotherapy for oligodendroglioma
73. Testing of a hypothesis of osmotic opening of the blood-brain barrier
74. Quantitative aspects of reversible osmotic opening of the blood-brain barrier
75. Controlled study of CCNU and radiation therapy in malignant astrocytoma
76. Long-term toxicity and neuropathology associated with sequencing of cranial irradiation and enhanced chemotherapy delivery
77. Age related chemosensitivity of stem cells from human malignant brain tumours
78. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulphate and procarbazine hydrochloride
79. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas
80. Morbidity and survival after BCNU wafer implantation for recurrent glioblastoma: A retrospective case matched cohort series
81. The clinical relevance of chemosensitivity testing in ovarian cancer
82. Assay of anti-cancer drugs in tissue culture: Relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma
83. In vitro chemosensitivity test of malignant gliomas: Clinical relevance of test results independent of adjuvant chemotherapy?
84. Chemotherapy for oligodendroglioma and glioma containing oligodendroglioma components
85. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomised double-blind study
86. He's not going to talk about in vitro predictive assays again, is he? Commentary
87. Intratumoral chemotherapy
88. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model
89. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms
90. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro
91. Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture
92. Interstitial chemotherapy of experimental gliomas
93. Strategies to circumvent vascular barriers of the central nervous system
94. Quantification and pharmacokinetics of blood-brain barrier disruption in humans